Sequential danazol/leuprolide acetate therapy for ovarian suppression in an in vitro fertilization patient unresponsive to leuprolide acetate
Case report
OA: closed
CC0
AI-generated summary
Sequential danazol/leuprolide acetate therapy achieved pituitary-ovarian suppression in an IVF patient unresponsive to leuprolide acetate alone, reducing estradiol levels and demonstrating a viable alternative for ovarian arrest.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
We report a case of pituitary-ovarian suppression obtained with sequential danazol/leuprolide acetate administration in a patient undergoing in vitro fertilization and unresponsive to leuprolide acetate alone and sequential oral contraceptive-leuprolide acetate therapy. Leuprolide acetate (1 mg daily subcutaneously) was administered after 5 weeks of danazol treatment (800 mg daily) while the latter was maintained for 1 additional week. Ovarian activity was assessed by transvaginal ultrasonography and serum estradiol determination. After 5 weeks of danazol therapy, ovarian arrest was obtained despite the fact that gonadotropin serum levels did not change relative to basal values. Leuprolide acetate injection for 14 days was associated with a decrease in serum concentrations of follicle-stimulating hormone and luteinizing hormone and a further decrease of the estradiol level. We conclude that sequential danazol/leuprolide acetate therapy is a useful alternative for obtaining ovarian arrest in patients unresponsive to leuprolide acetate alone.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
References (15)
- Danazol: endocrine pharmacology and therapeutic applications via crossref
- Danazol-induced pseudomenopause in the management of endometriosis via openalex
- Danazol-induced pseudomenopause in the management of endometriosis via crossref
- doi:10.1016/s0015-0282(16)56839-3 via openalex
- doi:10.1016/0002-9378(81)90611-6 via openalex
- doi:10.1016/s0015-0282(16)55448-x via openalex
- doi:10.1016/s0015-0282(16)54548-8 via openalex
- doi:10.1093/oxfordjournals.humrep.a137832 via crossref
- doi:10.1016/s0015-0282(16)55448-x via crossref
- doi:10.1016/s0015-0282(16)54548-8 via crossref
- doi:10.1016/s0015-0282(16)56595-9 via crossref
- doi:10.1016/s0015-0282(16)56595-9 via openalex
- doi:10.1016/s0015-0282(16)56839-3 via crossref
- doi:10.1093/oxfordjournals.humrep.a137832 via openalex
- W580619127 via openalex
Source provenance
- crossref
- last seen: 2026-09-13T06:26:05.004788+00:00
- openalex
- last seen: 2026-05-14T06:03:08.038466+00:00
- pubmed
- last seen: 2026-10-08T22:00:10.289599+00:00
- unpaywall
- last seen: 2026-10-19T06:34:38.229974+00:00
License: CC0
· commercial use OK